N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
The synthetic retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR; Fenretinide), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown. 4-HPR alone is a poor inducer of differentiation of HL-60 cells compared to all-trans-retinoic acid (RA). Here, we found that combinations of 4-HPR and RA synergistically induced differentiation of HL-60 cells. In addition, 4-HPR increased the level of retinoylation, the covalent binding of RA to proteins. Retinoylation occurs in many eukaryotic cell lines and may be involved in RA-induced differentiation. These results suggest that 4-HPR may be a member of a class of retinoids that are active because they displace RA from extracellular and intracellular sites or because they inhibit RA catabolism. On the basis of these proposed mechanisms, retinoids that do not cause differentiation as sole agents may have utility in the clinic in combination with RA.
Takahashi
N
N
Laboratory of Biological Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA.
Sausville
E A
EA
Breitman
T R
TR
D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects*; D004357:Drug Synergism; D017313:Fenretinide / Q000494:pharmacology*; D018922:HL-60 Cells; D006801:Humans; D007700:Kinetics; D009363:Neoplasm Proteins / Q000378:metabolism*; D014212:Tretinoin / Q000378:metabolism* / Q000494:pharmacology*
D016588:Anticarcinogenic Agents; D009363:Neoplasm Proteins; D017313:Fenretinide; D014212:Tretinoin